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Biotechnology May Help Thwart MalariaFor millions of Africans, the bite of
a mosquito is more than a nuisance;
it means malaria. Malaria is caused
by a parasite of the Plasmodium
family, transmitted to humans
through the bite of the Anopheles
mosquito.
As the infected mosquito feeds, it
injects a small amount of saliva as
well as Plasmodium sporozoites,
the ‘‘spore’’ of the Plasmodium.
The sporozoites are carried by the
bloodstream to the liver within min-
utes. The sporozoites infect the
liver, where they rapidly asexually
reproduce over 1 or 2 weeks. Some
sporozoites transform into mero-
zoites, which emerge to infect red
blood cells, and divide, bursting
apart the blood cells in a chain reac-
tion, spewing out more merozoites.
This stage, lasting 2 days, is charac-
terized by chills, anemia, fever, and
fatigue. The next mosquito that bites
the infected person ingests the mer-
ozoites, which sexually reproduce
in the mosquito’s guts, producing
sporozoites that migrate into its sa-
liva glands. The parasites that re-
main in the liver can stay dormant
for weeks or years until the next ma-
laria attack.
The acute form of the disease kills
an estimated one to three million
people a year. The nonlethal form
debilitates millions more. Small chil-
dren and pregnant women are
particularly vulnerable. Malaria is
a low-profile disease in the devel-
oped world because it occurs
mainly in impoverished countries.
Malaria infections can be prevented
by eliminating the mosquito vector,
but in sub-Saharan Africa, a region
plagued by everything from political
instability to famines, the lack of ba-
sic services make any attempt to en-
tirely eliminate the mosquito futile.
Anopheles is increasingly resistant
to cheap insecticides like DDT, and
the lethal strain of P. falciparum
is becoming resistant to common
medications. The result is that de-
spite all efforts, deaths from malaria
have increased over the last 20years. New biotechnology initiatives
aim to reverse this trend.
Gin and Tonic, Anyone?
Quinine, extracted from the bark of
the Peruvian Chinchona tree, was
known to the indigenous population
and was adopted by Spanish mis-
sionaries in the early seventeenth
century as a malarial prophylactic.
Quinine can lessen the severity of at-
tacks, but only destroys the parasite
in the blood. Chloroquine and
sulphadoxine-pyrimethamine have
been cheap, effective remedies but
have been misused. As a result, re-
sistant strains of the parasite have
already rendered these formerly
frontline drugs mostly useless.
Despite all efforts, deaths
from malaria have in-
creased over the last 20
years. New biotechnol-
ogy initiatives aim to re-
verse this trend.
Currently, the most effective drug
against malaria is artemisinin, first
extracted in the 1970s by Chinese
researchers from the Qinghao (Arte-
misia annua) or sweet wormwood
plant. Currently, the World Health
Organization (WHO) recommends
an artemisinin-based combination
therapy (ACT). Coartem, manufac-
tured by Novartis under a WHO con-
tract, is a three-dose Artemether-
lumefantrine combination therapy.
(Artekin, a cheaper ACT, is currently
used in Cambodia, China, and Viet-
nam but is not yet approved for in-
ternational use.) The ACT’s high
price of $1.20 to $2.40 a dose is
due to the limited availability of arte-
misinin, which is extracted from an
18 month old plant. It is considered
too expensive for wide use, com-
pared to earlier drugs at 20 cents
a dose.‘‘I’m a big supporter of artemisi-
nin-based combination therapy,’’
says Dr. Grant Dorsey, Assistant
Adjunct Professor at UCSF, who
has done years of clinical work in
Uganda. ‘‘There are some ques-
tions. The artemisinins are the best
drugs we have. They are the only
class of drugs that produce no resis-
tance, kill the asexual form of the
parasite, and are extremely rapid
acting.’’ But as artemisinins are so
short acting, they must be adminis-
tered in a cocktail with a longer lived
drug, he says. Moreover, they are
not a panacea, as patients get re-
infected. Dorsey advocated a ‘‘multi-
faceted approach’’ distributing
insecticide treated bed nets, provid-
ing speedy diagnostics, intermittent
preventative treatment in infants,
and spraying residual insecticides
inside houses.
Bioengineering Medicine
from Wormwood
Because of the scarce availability of
the drug and the fact that a fully syn-
thetic route is complicated, a bio-
technology approach seemed to be
obvious. However, early bioengi-
neered processes for the production
of artemisinin yielded low concen-
trations of the substance.
A promising process was devel-
oped in the laboratory of Professor
Jay Keasling at UC Berkeley and
licensed royalty free to OneWorld-
Health, a nonprofit drug company
based in San Francisco. OneWorld-
Health has received $42 million
from the Gates Foundation to com-
mercialize an affordable semisyn-
thetic source of artemisinin. Keas-
ling’s startup, Amyris, (http://www.
amyrisbiotech.com/), located in
Emeryville, CA, is bioengineering
E. coli to produce a precursor for ar-
temisinin. The precursor is isolated
from the soup of growth media and
chemically modified to obtain arte-
misinin. The precursors that Amyris
produces with their technology
could be used for other drugs, like
Taxol, extracted from the Pacific
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cancer treatments and isoprenoids
for the flavor and fragrance industry,
says Keasling. Once the process is
optimized, OneWorldHealth will li-
cense the manufacture of the semi-
synthetic artemisinin to reduce the
price of the combination therapy to
below a dollar.
Vaccinating against a Devious Foe
‘‘Plasmodium falciparum kills more
children in the world than any other
infectious agent,’’ says Dr. Stephen
Hoffman, CEO and founder of
Sanaria (http://www.sanaria.com/),
a Rockville, MD vaccine company.
‘‘Malaria is curable with current
drugs if caught early, but the prob-
lem is getting diagnosed in time.’’ It
is also a matter of the intensity of
transmission. Just one parasite in-
jectedby amosquito is enough toget
infected. Hoffman says, ‘‘In the areas
of Africa where we work, during ma-
laria season, every child is bitten by
a mosquito every day and some-
times two or three times a day. The
chance of getting infected is 100%
every day.’’ Thus, the ideal remedy
is a vaccine, Hoffman concludes.
But the complicated lifecycle of
the parasite makes developing ef-
fective vaccines a challenge. P. fal-
ciparum expresses numerous anti-
gens on its surface over its life
cycle, complicating antibody recog-
nition. Once it is inside the liver cells,
the body’s immune system does not
detect the parasite. Natural immu-
nity to malaria is partial and short
lived, leading to reoccurrences or
new infections. Even so, there are
around 50 vaccine candidates under
development worldwide, several in
clinical trials. Conservative esti-
mates are that they are at least 10
years away from a worldwide roll
out.
Nevertheless, in October 2005,
the Gates Foundation gave $107
million to the PATH Malaria Vaccine
Initiative (MVI) the organization the
Gates Foundation had established
to collaborate with GlaxoSmithKline
Biologicals (GSK) to do further de-
velopment and testing on GSK’s re-
combinant vaccine RTS,S/AS02A.
This vaccine is currently the candi-
date closest to actual use for infants
and children between 1 and 4 years
old. RTS,S, which has been under
development for 15 years, fuses
part of the P. falciparum circum-sporozoite protein with the hepatitis
B surface antigen molecule RTS,S.
‘‘We don’t know what the effective
vaccines are, and in my opinion,
we are looking to use them in con-
junction with other therapies,’’ says
Dr. Filip Dubovsky, Vice President
of Scientific Affairs at MVI. ‘‘We
now have pretty clear proof that
we’ve had a scientific breakthrough
in that we can impact disease, infec-
tion, and severe disease using a sin-
gle antigen. In our case, our vaccine
has one out of the 5200 proteins that
malaria carries. We can impact
those clinical disease patterns for
18 months.’’
However, this vaccine offers only
partial protection. In 2004, a proof-
of-concept study was carried out
under the aegis of the Manhic¸a
Health Research Centre (CISM) on
a group of 1442 children in Mozambi-
que ages 1 to 4 years. ‘‘In the 18
months of the study, RTS,S reduced
clinical disease by 35% and severe
disease by 48%,’’ Dubovsky says.
‘‘We thought there was a 29% lower
rate of infection in the vaccinated
group versus the control group. The
impact over 6 months was 45%.’’
Other vaccine approaches include
Transmission Blocking Vaccines
being developed at the National
Institute of Allergy and Infectious
Disease, which attempt to prevent
feeding mosquitoes from passing in-
fection, and the LSA-1 Liver Stage
Antigen that the Walter Reed Army
Institute of Research is pairing with
GSK’s adjuvant, AS02A. GenVec
(http://www.genvec.com/), a Mary-
land biotech company, is working
with MVI and the US Naval Medical
Research Center to develop a multi-
component vaccine that uses a hu-
man cold virus to carry genes for up
to five antigens (CSP, SSP2, LSA1,
MSP1, and AMA1) from different
stages of the parasite’s life cycle in
one vaccine.
Help Wanted: Sharp-Eyed
Mosquito Dissectors with
a Steady Hand
A unique strategy is being pursued
by Sanaria based on research show-
ing that short-lived immunity can be
induced by vaccination with the
sporozoites found in the saliva of in-
fected mosquitos. Sanaria’s vaccine
is aimed at preventing the parasite
not from entering the body but
from leaving the liver into the blood-stream. Their approach is distinct in
another way: ‘‘We are using an at-
tenuated whole parasite, meaning
weakened, live parasite,’’ says Hoff-
man. ‘‘It is the sporozoite, which is
the stage which is inoculated by
the mosquitos. And everyone else
is using a recombinant, modern ap-
proach, meaning recombinant pro-
tein or recombinant virus.’’
Sanaria’s vaccine is based upon
a classic technique of vaccine pro-
duction like the Sabin polio vaccine
and the vaccine for the flu. Research
conducted in the 1970s showed that
weakened sporozoites could confer
immunity. This was not further de-
veloped into a clinical vaccine be-
cause of the technical difficulties
in obtaining, stabilizing, and storing
a sufficient quantity of weakened
sporozoites, Hoffman says. But bio-
technology advances within the last
3 years have provided the company
with the tools to develop assays of
purity, potency, and safety as well as
improved understanding of the mo-
lecular biology of the parasite and
the means to efficiently culture it.
Sanaria irradiates infected mos-
quitoes to attenuate the parasite
and then manually dissects out the
mosquitoes’ salivary glands to get
the sporozoites—one mosquito at
a time by hand. ‘‘We have such
high production per mosquito,’’
says Hoffman. ‘‘Our dissectors are
so efficient that the way we think
about it is what a chip factory looks
like in Southeast Asia. Even produc-
ing 60 million doses a year won’t
take more than a hundred people.’’
Sanaria is funded by the Gates
Foundation, NIH, and the US Army.
OneWorldHealth is providing regu-
latory support.
If vivisection of mosquitoes can be
done on a mass scale, then modern-
izing an old vaccine technique may
be a viable strategy. ‘‘Can we bring
to bear modern bioengineering to
produce the quantities of these
sporozoites under aseptic condi-
tions, extract them from the mosqui-
toes, purify them, preserve them in
a bottle, and demonstrate that we
can inject them with a needle and sy-
ringe?’’ Hoffman asks. ‘‘Because if
we can do all of that, we have a real
vaccine with us right now.’’
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